Full-Time

Biologics Account Manager

Posted on 5/16/2026

Smith+Nephew

Smith+Nephew

10,001+ employees

Global medical devices for orthopedics

Compensation Overview

$60k - $100k/yr

+ Commission

Colorado Springs, CO, USA + 1 more

More locations: Denver, CO, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Requirements
  • Bachelor's degree or equivalent experience
  • Minimum 6 years direct sales experience with 4 years in medical device industry preferred
  • Experience with selling technology and/or capital products to multiple call points in the hospital, including surgeons, nursing, administration, facilities, bio-med and information systems preferred
  • Proven track record selling/converting business at the surgeon or hospital level
  • Proven success in achieving quota year over year
  • Experience leading/mentoring team members and new sales representatives
  • Travel requirements: within designated sales territory with 1-3 overnights a week depending on geography of territory. Infrequent national travel for events and conferences
  • All field sales professionals who are required to gain entry into healthcare facilities to perform the basic remit of their role must successfully complete the credentialing process and comply with the requirements of those facilities they support, which can include adherence to any established vaccine protocols.
Responsibilities
  • Exceed your sales quota and grow the Sports Medicine Biologics business within your territory.
  • Be a product consultant in the Sports Medicine Biologics portfolio specializing in both Biologics and Sports Medicine soft tissue injury repair.
  • Convert physicians/accounts by making sales calls and providing clinical case coverage in the operating room while also training surgeons on Smith+Nephew products through education/programs in your territory.
  • Collaborate with key orthopedic surgeons, hospital and operating room staff, administrators, and clinicians.
  • Work cross-divisionally to increase awareness and adoption of products including the Sports Medicine Biologics product portfolio.
Desired Qualifications
  • 4 years in medical device industry preferred
  • Experience with selling technology and/or capital products to multiple call points in the hospital, including surgeons, nursing, administration, facilities, bio-med and information systems preferred

Smith+Nephew is a global medical technology company that designs and makes medical devices for orthopaedics, sports medicine, and advanced wound care. Its products help surgeons treat joints and soft tissues and support patient recovery, including knee repair systems, single-use negative pressure wound therapy devices, and other extremity orthopaedic products. These devices are used in hospitals and clinics to perform procedures and support healing, often after surgery or injury. The company differentiates itself with a broad, worldwide product portfolio and collaborations with healthcare organizations to improve care and efficiency for patients and providers. Its goal is to improve patient outcomes, streamline medical procedures, and expand access to advanced medical solutions around the world.

Company Size

10,001+

Company Stage

IPO

Headquarters

Watford, United Kingdom

Founded

1856

Simplify Jobs

Simplify's Take

What believers are saying

  • LEAF reduces pressure injury odds 73% and saves critical care facilities $1.8 million.
  • Integrity Orthopaedics adds rotator cuff repair technology to a large US procedure market.
  • Atracsys expands digital surgery capabilities across robotics, knees, hips, and shoulders.

What critics are saying

  • Q1 organic sales growth of 3.1% missed consensus, signaling execution pressure.
  • Chinese pricing reforms and US reimbursement changes directly pressure 2026 revenue and margins.
  • Integration risk remains high across Atracsys, Integrity Orthopaedics, and partner-led portfolio expansion.

What makes Smith+Nephew unique

  • Portfolio medtech focused on soft and hard tissue repair, regeneration, and replacement.
  • Leverages orthopaedics, sports medicine, and advanced wound management across 100 countries.
  • Combines digital surgery, monitoring, and wound technologies with hospital workflow integration.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Smith+Nephew who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Parental Leave

Fertility Treatment Support

Family Planning Benefits

Tuition Reimbursement

Wellness Program

Mental Health Support

Volunteer Time Off

Home Office Stipend

Phone/Internet Stipend

Discounted Stock Options

Health Savings Account/Flexible Spending Account

Employee Assistance Program

PTO/vacation?

Paid Sick Leave

Company News

Yahoo Finance
Mar 4th, 2026
Smith & Nephew reports $6.2B revenue with 5.3% growth and 53% jump in free cash flow

Smith & Nephew reported strong full-year 2025 results, with revenue of $6.2 billion representing 5.3% underlying growth and 6.1% reported growth. Fourth-quarter revenue reached $1.7 billion, growing 6.2% on an underlying basis. The medical device company achieved 160 basis points of margin expansion, with trading profit of $1.2 billion and adjusted earnings per share of $1.02, up 21%. Free cash flow increased 52.5% year-on-year to $840 million, enabling completion of a $500 million share buyback programme. Innovation drove over 60% of growth, with products launched in the past five years delivering double-digit growth across all business units. For 2026, the company expects 6% organic revenue growth and 8% trading profit growth to around $1.3 billion, though it faces headwinds from Chinese pricing reforms and US reimbursement changes.

Yahoo Finance
Feb 25th, 2026
Smith & Nephew signs exclusive US distribution deal with RMR Ortho for A'TOMIC Nitinol Fixation System

Smith+Nephew has signed an exclusive US distribution agreement with RMR Ortho to add the A'TOMIC Nitinol Fixation System to its Trauma, Foot & Ankle and Hand & Wrist portfolio. The partnership enables Smith+Nephew to expand its participation in high-frequency fracture and arthrodesis procedures whilst utilising its existing Extremities and Trauma sales channel. The dynamic compression fixation solution complements the company's current technologies. Scott Gunn, Vice President of US Marketing at Smith+Nephew, said the collaboration reflects the company's disciplined approach to portfolio expansion and continued focus on driving sustainable growth.

Investegate Ltd
Jan 12th, 2026
Smith+Nephew acquires Integrity Orthopaedics for $225M plus $225M in performance payments

Smith+Nephew has acquired Integrity Orthopaedics for an initial $225 million cash payment, plus up to $225 million in performance-based payments over five years. The deal strengthens Smith+Nephew's sports medicine portfolio with the Tendon Seam rotator cuff repair technology. Founded in 2020, Integrity Orthopaedics developed the innovative system to address high failure rates in traditional rotator cuff repairs. The technology uses patented micro-anchors and continuous suture designed to deliver stronger repairs and lower re-tear rates. Early clinical results show reduced pain and shorter recovery times. The rotator cuff repair market performs approximately 500,000 procedures annually in the US, valued at $875 million. The acquisition, expected to close by end of January 2026, will be financed from existing cash facilities and is expected to be accretive to trading profit margin by 2028.

Startupticker.ch
Jun 2nd, 2025
Smith & Nephew acquires Atracsys to expand its digital surgery ecosystem

Download the Swiss reference publication on investments, investors and exits in our assets section.

The Manila Times
Mar 11th, 2025
Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025

Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for robotics, knees, hips, and shoulders at AAOS 2025.

INACTIVE